EDX Medical Group - Exercise of Warrants

4 March 2026

EDX Medical Group plc

("EDX Medical" or the "Company")

Exercise of Warrants

CAMBRIDGE, UK: EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces that a warrant holder has agreed to exercise their warrants over ordinary shares in EDX Medical, in accordance with the terms of the warrant instrument.

The warrants were issued at an exercise price of 10p per ordinary share to the first warrant holders of TECC Capital plc ("TECC").   EDX Medical Ltd was acquired by TECC via a reverse takeover in 2022, upon which TECC then changed its name to EDX Medical Group plc.

The Company has a remaining 12,100,000 warrants in place with an exercise price of 10p per ordinary share and 12,500,000 with an exercise price of 20p per ordinary share.

Application will be made for the newly issued shares to be admitted to trading on the Aquis Stock Exchange and it is expected that admission will occur on 10 March 2026.

Following this warrant exercise, the Company has 411,844,583 ordinary shares in issue, each share carrying the right to one vote.  This figure serves as the denominator for shareholders to calculate their notification requirements under the Financial Conduct Authority's Disclosure and Transparency Rules regarding their interests in the company's share capital.

The directors of EDX Medical accept responsibility for the contents of this announcement.

ENDS

Contacts:

Notes to Editors:

About EDX Medical Group plc

EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical  provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com